PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress

Tatsuyoshi Kono, Geonyoung Ahn, Dan R. Moss, Liann Gann, Angel Zarain-Herzberg, Yurika Nishiki, Patrick T. Fueger, Takeshi Ogihara, Carmella Evans-Molina

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The maintenance of intracellular Ca 2+ homeostasis in the pancreatic β-cell is closely regulated by activity of the sarco-endoplasmic reticulum Ca 2+ ATPase (SERCA) pump. Our data demonstrate a loss of β-cell SERCA2b expression in several models of type 2 diabetes including islets from db/db mice and cadaveric diabetic human islets. Treatment of 832/13 rat INS-1-derived cells with 25 mm{cyrillic} glucose and the proinflammatory cytokine IL-1 β led to a similar loss of SERCA2b expression, which was prevented by treatment with the peroxisome proliferator-activated receptor (PPAR)-γ agonist, pioglitazone. Pioglitazone was able to also protect against hyperglycemia and cytokineinduced elevations in cytosolic Ca 2+ levels, insulin-secretory defects, and cell death. To determine whether PPAR-γ was a direct transcriptional regulator of the SERCA2 gene, luciferase assays were performed and showed that a-259 bp region is sufficient to confer PPAR-γ transactivation; EMSA and chromatin immunoprecipitation experiments confirmed that PPAR-γ directly binds a PPAR response element in this proximal region. We next sought to characterize the mechanisms by which SERCA2b was down-regulated. INS-1 cells were exposed to high glucose and IL-1β in time course experiments. Within 2 h of exposure, activation of cyclin-dependent kinase 5 (CDK5) was observed and correlated with increased serine-273 phosphorylation of PPAR-γ and loss of SERCA2 protein expression, findings that were prevented by pioglitazone and roscovitine, a pharmacological inhibitor of CDK5. We conclude that pioglitazone modulates SERCA2b expression through direct transcriptional regulation of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR-γ.

Original languageEnglish (US)
Pages (from-to)257-271
Number of pages15
JournalMolecular Endocrinology
Volume26
Issue number2
DOIs
StatePublished - Jan 1 2012

Fingerprint

pioglitazone
Peroxisome Proliferator-Activated Receptors
Islets of Langerhans
Cytokines
Cyclin-Dependent Kinase 5
Interleukin-1
Phosphorylation
Glucose
Chromatin Immunoprecipitation
Response Elements
Regulator Genes
Luciferases
Hyperglycemia
Endoplasmic Reticulum
Serine
Type 2 Diabetes Mellitus
Transcriptional Activation
Adenosine Triphosphatases
Homeostasis
Cell Death

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. / Kono, Tatsuyoshi; Ahn, Geonyoung; Moss, Dan R.; Gann, Liann; Zarain-Herzberg, Angel; Nishiki, Yurika; Fueger, Patrick T.; Ogihara, Takeshi; Evans-Molina, Carmella.

In: Molecular Endocrinology, Vol. 26, No. 2, 01.01.2012, p. 257-271.

Research output: Contribution to journalArticle

Kono, Tatsuyoshi ; Ahn, Geonyoung ; Moss, Dan R. ; Gann, Liann ; Zarain-Herzberg, Angel ; Nishiki, Yurika ; Fueger, Patrick T. ; Ogihara, Takeshi ; Evans-Molina, Carmella. / PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. In: Molecular Endocrinology. 2012 ; Vol. 26, No. 2. pp. 257-271.
@article{34169083d34147f099551afca728e99a,
title = "PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress",
abstract = "The maintenance of intracellular Ca 2+ homeostasis in the pancreatic β-cell is closely regulated by activity of the sarco-endoplasmic reticulum Ca 2+ ATPase (SERCA) pump. Our data demonstrate a loss of β-cell SERCA2b expression in several models of type 2 diabetes including islets from db/db mice and cadaveric diabetic human islets. Treatment of 832/13 rat INS-1-derived cells with 25 mm{cyrillic} glucose and the proinflammatory cytokine IL-1 β led to a similar loss of SERCA2b expression, which was prevented by treatment with the peroxisome proliferator-activated receptor (PPAR)-γ agonist, pioglitazone. Pioglitazone was able to also protect against hyperglycemia and cytokineinduced elevations in cytosolic Ca 2+ levels, insulin-secretory defects, and cell death. To determine whether PPAR-γ was a direct transcriptional regulator of the SERCA2 gene, luciferase assays were performed and showed that a-259 bp region is sufficient to confer PPAR-γ transactivation; EMSA and chromatin immunoprecipitation experiments confirmed that PPAR-γ directly binds a PPAR response element in this proximal region. We next sought to characterize the mechanisms by which SERCA2b was down-regulated. INS-1 cells were exposed to high glucose and IL-1β in time course experiments. Within 2 h of exposure, activation of cyclin-dependent kinase 5 (CDK5) was observed and correlated with increased serine-273 phosphorylation of PPAR-γ and loss of SERCA2 protein expression, findings that were prevented by pioglitazone and roscovitine, a pharmacological inhibitor of CDK5. We conclude that pioglitazone modulates SERCA2b expression through direct transcriptional regulation of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR-γ.",
author = "Tatsuyoshi Kono and Geonyoung Ahn and Moss, {Dan R.} and Liann Gann and Angel Zarain-Herzberg and Yurika Nishiki and Fueger, {Patrick T.} and Takeshi Ogihara and Carmella Evans-Molina",
year = "2012",
month = "1",
day = "1",
doi = "10.1210/me.2011-1181",
language = "English (US)",
volume = "26",
pages = "257--271",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress

AU - Kono, Tatsuyoshi

AU - Ahn, Geonyoung

AU - Moss, Dan R.

AU - Gann, Liann

AU - Zarain-Herzberg, Angel

AU - Nishiki, Yurika

AU - Fueger, Patrick T.

AU - Ogihara, Takeshi

AU - Evans-Molina, Carmella

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The maintenance of intracellular Ca 2+ homeostasis in the pancreatic β-cell is closely regulated by activity of the sarco-endoplasmic reticulum Ca 2+ ATPase (SERCA) pump. Our data demonstrate a loss of β-cell SERCA2b expression in several models of type 2 diabetes including islets from db/db mice and cadaveric diabetic human islets. Treatment of 832/13 rat INS-1-derived cells with 25 mm{cyrillic} glucose and the proinflammatory cytokine IL-1 β led to a similar loss of SERCA2b expression, which was prevented by treatment with the peroxisome proliferator-activated receptor (PPAR)-γ agonist, pioglitazone. Pioglitazone was able to also protect against hyperglycemia and cytokineinduced elevations in cytosolic Ca 2+ levels, insulin-secretory defects, and cell death. To determine whether PPAR-γ was a direct transcriptional regulator of the SERCA2 gene, luciferase assays were performed and showed that a-259 bp region is sufficient to confer PPAR-γ transactivation; EMSA and chromatin immunoprecipitation experiments confirmed that PPAR-γ directly binds a PPAR response element in this proximal region. We next sought to characterize the mechanisms by which SERCA2b was down-regulated. INS-1 cells were exposed to high glucose and IL-1β in time course experiments. Within 2 h of exposure, activation of cyclin-dependent kinase 5 (CDK5) was observed and correlated with increased serine-273 phosphorylation of PPAR-γ and loss of SERCA2 protein expression, findings that were prevented by pioglitazone and roscovitine, a pharmacological inhibitor of CDK5. We conclude that pioglitazone modulates SERCA2b expression through direct transcriptional regulation of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR-γ.

AB - The maintenance of intracellular Ca 2+ homeostasis in the pancreatic β-cell is closely regulated by activity of the sarco-endoplasmic reticulum Ca 2+ ATPase (SERCA) pump. Our data demonstrate a loss of β-cell SERCA2b expression in several models of type 2 diabetes including islets from db/db mice and cadaveric diabetic human islets. Treatment of 832/13 rat INS-1-derived cells with 25 mm{cyrillic} glucose and the proinflammatory cytokine IL-1 β led to a similar loss of SERCA2b expression, which was prevented by treatment with the peroxisome proliferator-activated receptor (PPAR)-γ agonist, pioglitazone. Pioglitazone was able to also protect against hyperglycemia and cytokineinduced elevations in cytosolic Ca 2+ levels, insulin-secretory defects, and cell death. To determine whether PPAR-γ was a direct transcriptional regulator of the SERCA2 gene, luciferase assays were performed and showed that a-259 bp region is sufficient to confer PPAR-γ transactivation; EMSA and chromatin immunoprecipitation experiments confirmed that PPAR-γ directly binds a PPAR response element in this proximal region. We next sought to characterize the mechanisms by which SERCA2b was down-regulated. INS-1 cells were exposed to high glucose and IL-1β in time course experiments. Within 2 h of exposure, activation of cyclin-dependent kinase 5 (CDK5) was observed and correlated with increased serine-273 phosphorylation of PPAR-γ and loss of SERCA2 protein expression, findings that were prevented by pioglitazone and roscovitine, a pharmacological inhibitor of CDK5. We conclude that pioglitazone modulates SERCA2b expression through direct transcriptional regulation of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR-γ.

UR - http://www.scopus.com/inward/record.url?scp=84856262896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856262896&partnerID=8YFLogxK

U2 - 10.1210/me.2011-1181

DO - 10.1210/me.2011-1181

M3 - Article

C2 - 22240811

AN - SCOPUS:84856262896

VL - 26

SP - 257

EP - 271

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 2

ER -